New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
08:05 EDTBSTC, AUXLBioSpecifics announces postive data from Xiaflex Phase IIa study
BioSpecifics (BSTC) announced positive, statistically significant top-line data from the Phase IIa study of Xiaflex for the potential treatment of frozen shoulder. This open-label, controlled dose-ranging Phase IIa study was conducted by BioSpecifics' strategic partner Auxilium (AUXL) and was designed to assess the safety and efficacy of Xiaflex for the treatment of Stage 2 unilateral idiopathic frozen shoulder in comparison to an exercise-only control group. Both the 0.58mg and 0.58mg dosing arms showed positive, statistically significant improvement from baseline in forward flexion vs. the exercise-only group. There were no drug-related serious adverse events reported and all treatment-related adverse events were consistent with XIAFLEX use in other approved and potential indications.
News For BSTC;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:13 EDTAUXLAuxilium reports Q3 EPS 27c, consensus 10c
Subscribe for More Information
October 21, 2014
08:13 EDTAUXL, BSTCBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use